Junquero et al., 1992 - Google Patents
Inhibition of cytokine‐induced nitric oxide production by transforming growth factor‐beta 1 in human smooth muscle cells.Junquero et al., 1992
View PDF- Document ID
- 2909952964003418162
- Author
- Junquero D
- Scott‐Burden T
- Schini V
- Vanhoutte P
- Publication year
- Publication venue
- The Journal of Physiology
External Links
Snippet
1. Experiments were performed to investigate the effects of human recombinant interleukin‐ 1 beta on the production of vasoactive substances by human aortic smooth muscle cells in culture. Smooth muscle cells were cultured either on microcarrier beads for bioassay …
- 210000000329 Myocytes, Smooth Muscle 0 title abstract description 43
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K8/00—Cosmetic or similar toilet preparations
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Junquero et al. | Inhibition of cytokine‐induced nitric oxide production by transforming growth factor‐beta 1 in human smooth muscle cells. | |
| Koide et al. | Cyclic AMP-elevating agents induce an inducible type of nitric oxide synthase in cultured vascular smooth muscle cells. Synergism with the induction elicited by inflammatory cytokines. | |
| US5073492A (en) | Synergistic composition for endothelial cell growth | |
| Abraham et al. | Vanillin, a potential agent for the treatment of sickle cell anemia | |
| EP0196415B1 (en) | Trichostatins a and c as antitumour drugs | |
| Boxer et al. | Inhibition of polymorphonuclear leukocyte adherence by prostacyclin | |
| Pipili‐Synetos et al. | Evidence that nitric oxide is an endogenous antiangiogenic mediator | |
| Coffey Jr et al. | Suramin inhibition of growth factor receptor binding and mitogenicity in AKR‐2B cells | |
| Loesberg et al. | Cell cycle-dependent inhibition of human vascular smooth muscle cell proliferation by prostaglandin E1 | |
| Kim et al. | Reduced production of cGMP underlies the loss of endothelium-dependent relaxations in the canine basilar artery after subarachnoid hemorrhage. | |
| Zhao et al. | Reduced glutathione prevents nitric oxide-induced apoptosis in vascular smooth muscle cells | |
| Wenzel et al. | Effects of nicotine on cultured rat heart cells | |
| RODRÍGUEZ-LIÑARES et al. | Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation | |
| CA2147123C (en) | Use of a cell membrane permeant calcium buffer for reducing injury of mammalian cells in vivo | |
| JP2001511151A (en) | How to treat epidermis or skin disease and transformed animals | |
| Ross | Platelets: cell proliferation and atherosclerosis | |
| Hasselgren et al. | Effect of indomethacin on proteolysis in septic muscle. | |
| Fahey et al. | Human synovial fibroblasts: the relationships between cyclic AMP, bradykinin, and prostaglandins | |
| Honma et al. | Induction by some protein kinase inhibitors of differentiation of a mouse megakaryoblastic cell line established by coinfection with Abelson murine leukemia virus and recombinant SV40 retrovirus | |
| Meijer et al. | Immobilized methylglyoxal-bis (guanylhydrazone) induces starfish oocyte maturation | |
| Center et al. | Alteration of rat splenic lymphocyte migration in vitro by the state of microtubule integrity | |
| Prasad | Induction of differentiated phenotypes in melanoma cells by a combination of an adenosine 3′, 5′-cyclic monophosphate stimulating agent and D-alpha tocopheryl succinate | |
| Duperray et al. | Effect of mitomycin C on prostacyclin synthesis by human endothelial cells | |
| Leszczynski et al. | IL‐1β‐Stimulated Leucocyte–Endothelial Adhesion is Regulated, in Part, by the Cyclic‐GMP‐Dependent Signal Transduction Pathway | |
| Ross et al. | Platelets, endothelium, and smooth muscle cells in atherosclerosis |